
|Videos|April 6, 2016
Episode 2: Dr. Fajgenbaum’s Commentary
Advertisement
- After episode 1, patient was discharged and out of hospital for almost 4 weeks
- Diuresed 42 pounds of fluid and began to feel well again
- Toward end of 4-weeks, patient started to experience same symptoms he had before first hospitalization:
- Enlargement of lymph nodes, fatigue and night sweats, and abdominal pain
- Lab tests performed, as well as CT scan, which found extensive lymphadenopathy throughout the body
- Lymph node biopsy performed
- 4 important findings:
- Regressed germinal centers
- Plasmacytosis
- Hyperplastic follicles
- Extreme vascularization throughout lymph node
- 4 important findings:
- Multicentric Castleman Disease suspected
- Additional testing warranted to rule out other disorders
- No signs of monoclonality within lymph node; other disorders already ruled out
- Determined to be Multicentric Castleman Disease
- Tests conducted to determine whether HHV-8negative or HHV-8–positive Multicentric Castleman Disease
- Based on negative LANA-1 staining and negative PCR for HHV-8, HHV-8 negative Multicentric Castleman Disease was determined
- Patient sent back to hospital and started on rituximab
- Patient did not respond right away
- Within 48 hours, improvements in laboratory values observed
- BUN, which peaked over 200, began to improve
- Creatinine, which was over 2, began to improve
- CRP, which was over 300 at its peak, started to improve within couple days of starting rituximab
- Patient achieves partial remission on rituximab and is healthy enough to leave hospital
- Not yet in complete remission
Read through the episodes of one patient’s journey toward an accurate diagnosis and listen to an expert’s analysis on each episode.
Advertisement
Related to this article

The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.

Anbal-cel demonstrated a 67.1% complete response rate in relapsed or refractory LBCL in the phase 1/2 CRC01-01 trial, evaluating dual PD-1 and TIGIT knockdown CAR T-cell therapy.
Advertisement
Advertisement
Trending on Targeted Onc
1
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
4
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
5




